A carregar...
Rituximab efficiently depletes increased CD20 expressing T cells in multiple sclerosis patients()
In multiple sclerosis (MS()) B cell depleting therapy using monoclonal anti-CD20 antibodies, including rituximab (RTX) and ocrelizumab (OCR), effectively reduces disease activity. Based on indirect evidence, it is generally believed that elimination of the antigen presenting capabilities and antigen...
Na minha lista:
| Main Authors: | , , , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2014
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4082756/ https://ncbi.nlm.nih.gov/pubmed/24928997 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4049/jimmunol.1400118 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|